Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL277090 | 0.87 | TSHR (0.38) | TSHRTDP1 | |
| SCHEMBL13273750 | 0.71 | TSHR (0.35) | TSHRTDP1 | |
| SCHEMBL411803 | 0.67 | TSHR (0.38) | TSHRTDP1 | |
| SCHEMBL18612961 | 0.67 | TSHR (0.38) | TSHRTDP1 | |
| SCHEMBL12285415 | 0.67 | TSHR (0.38) | TSHRTDP1 | |
| SCHEMBL27688515 | 0.63 | — | — | |
| SCHEMBL22751138 | 0.63 | TSHR (0.35) | TSHRTDP1 | |
| SCHEMBL21539097 | 0.62 | TSHR (0.33) | TSHRTDP1 | |
| SCHEMBL4930606 | 0.62 | TSHR (0.33) | TSHRTDP1 | |
| SCHEMBL49720 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230241012-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2023-08-03 | — | — | US | disclosed |
| US-10952978-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-10280175-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2019-05-07 | — | — | US | disclosed |
| US-20170217974-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217974-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, ZC3HAV1, SLC10A1 | TSHR 2206/4885TDP1 3947/4885 |
| US-10952978-B2 | Hepatitis B antiviral agents | HAVCR2, PYGL, SLC10A1 | TSHR 2628/4885TDP1 3722/4885 |
| US-20230241012-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, PYGL, SLC10A1 | TSHR 2628/4885TDP1 3722/4885 |
| US-10280175-B2 | Hepatitis B antiviral agents | ZC3HAV1, HAVCR2, SLC10A1 | TSHR 2861/4885TDP1 4001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.